GRAYROBINSON PA

Lobbying for OMEROS CORPORATION · Biopharmaceutical company focused on small-molecule and protein therapeutics.

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2025 · Washington · House · Senate · $45,000.00 income · posted Apr 20, 2025

Lobbying activity 1

Medicare/Medicaid

Separate payment policies for non-opioid alternatives.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.